1.
Cyclosporin A, an immunosuppressive
drug used to treat
psoriasis, stimulates renal synthesis of
1,25-dihydroxyvitamin D in rats.
1,25-Dihydroxyvitamin D can also reduce the activity of
psoriasis, and in the present study we have examined the possibility that
cyclosporin A mediates some of its actions in
psoriasis by renal or extra-renal production of
1,25-dihydroxyvitamin D. 2. Treatment of 12 psoriatic patients with
cyclosporin A (5 mg day-1 kg-1) for 3 months significantly improved the
psoriasis activity and severity index and reduced glomerular filtration rate, but serum
1,25-dihydroxyvitamin D levels were not changed. However, 1-3 months after stopping
cyclosporin A treatment, an increase in the
psoriasis activity and severity index score was accompanied by a small, but significant, increase in serum
1,25-dihydroxyvitamin D concentration. Plasma
1,25-dihydroxyvitamin D levels in rats gavaged with
cyclosporin A (15 mg day-1 kg-1 for 2 weeks) were significantly increased compared with controls, but a lower dose of
cyclosporin A (2.4 mg day-1 kg-1) had no effect. Renal 25-hydroxyvitamin D-24-hydroxylase activity in rat kidney homogenates was not different between control and
cyclosporin A-treated rats. Renal 25-hydroxyvitamin D-1 alpha-
hydroxylase activity was not detectable in these homogenates. Extra-renal production of
1,25-dihydroxyvitamin D by activated macrophages isolated from the synovial fluid of patients with inflammatory
arthritis was reduced after incubation with
cyclosporin A (0.1-10 mumol/l) for 30 h or 5 days.(ABSTRACT TRUNCATED AT 250 WORDS)